IDH-mutant gliomas are the most common gliomas of young adults. Despite initial sensitivity to chemotherapy
and radiation, they invariably progress as treatment resistant lesions to become ultimately fatal. The unique
metabolic phenotype of IDH-mutant glioma leaves malignant cells potentially vulnerable to several candidate
therapies or therapeutic combination. There remains an urgent unmet need for a reliable quantitative monitoring
biomarker to accelerate translational progress Since disease course frequently extends over several years,
patient-centric models of therapeutic discovery could leverage reliable surrogate outcomes toward iterative
refinement of individualized therapies. This project utilizes a phased, milestone-driven feasibility, discovery (R61;
Aims 1-2) and validation analysis (R33; Aims 3-4) of D2-HG as a candidate biomarker of IDH-mutant glioma.
This study takes advantage of neurosurgical access to the CNS, wherein CSF access devices utilized for clinical
management may be deployed for longitudinal CSF access as an adjunct to lumbar puncture. Moreover, it utilizes
tumor-based benchmarks for D2-HG content and production within the tumor based on analysis of tumor tissue
We hypothesize that CSF D2-HG represents a useful monitoring biomarker for IDH-
mutant glioma to help quantify response to therapy and identify disease recurrence. To test this
hypothesis, we propose the following aims:
Aim 1: Determine the technical and biological performance characteristics of CSF D2-HG as a biomarker
of IDH-mutant glioma. Detailed and rigorous analyses will be performed for D2-HG and its mass spectroscopy
assay including stability, precision, accuracy, interference, and technical as well as biological variance upon
repeated measurements and correlates to tumor properties based upon gold-standard benchmarks.
Aim 2: Determine a baseline threshold value of CSF D2-HG diagnostic for IDH-mutant glioma and define
the minimal percent change indicative of altered disease burden. Appropriate ROC models will be built with
and AUC analysis to define a threshold diagnostic of IDH-mutant glioma. Cross-sectional patient cohorts will be
used to evaluate responsiveness of D2HG to therapy and disease progression
Aim 3: Validate CSF D2HG as a biomarker of therapeutic response. CSF D2-HG will be evaluated
longitudinally in to validate responsiveness to therapy as benchmarked modified RANO criteria.
Aim 4: Evaluate CSF D2HG as a biomarker of disease progression. A cumulative cross-sectional cohort of
patients with verified IDH-mutant gliomas will be followed longitudinally during disease monitoring for recurrent
disease to validate the defined threshold indicative of disease progression.